Annual Accounts Payable
$3.80 M
+$211.00 K+5.88%
December 31, 2023
Summary
- As of February 7, 2025, HRTX annual accounts payable is $3.80 million, with the most recent change of +$211.00 thousand (+5.88%) on December 31, 2023.
- During the last 3 years, HRTX annual accounts payable has risen by +$3.17 million (+503.97%).
- HRTX annual accounts payable is now -79.92% below its all-time high of $18.92 million, reached on December 31, 2017.
Performance
HRTX Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$10.19 M
-$38.00 K-0.37%
September 30, 2024
Summary
- As of February 7, 2025, HRTX quarterly accounts payable is $10.19 million, with the most recent change of -$38.00 thousand (-0.37%) on September 30, 2024.
- Over the past year, HRTX quarterly accounts payable has dropped by -$38.00 thousand (-0.37%).
- HRTX quarterly accounts payable is now -46.14% below its all-time high of $18.92 million, reached on December 31, 2017.
Performance
HRTX Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
HRTX Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +5.9% | -0.4% |
| 3 y3 years | +504.0% | +73.1% |
| 5 y5 years | -77.8% | +526.2% |
HRTX Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -1.9% | +5.9% | -26.2% | +1117.2% |
| 5 y | 5-year | -1.9% | +504.0% | -44.8% | +1519.7% |
| alltime | all time | -79.9% | +2289.3% | -46.1% | >+9999.0% |
Heron Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $10.19 M(-0.4%) |
| Jun 2024 | - | $10.23 M(+1121.7%) |
| Mar 2024 | - | $837.00 K(-78.0%) |
| Dec 2023 | $3.80 M(+5.9%) | $3.80 M(+104.2%) |
| Sep 2023 | - | $1.86 M(-5.0%) |
| Jun 2023 | - | $1.96 M(-51.9%) |
| Mar 2023 | - | $4.07 M(+13.3%) |
| Dec 2022 | $3.59 M(-7.4%) | $3.59 M(-45.2%) |
| Sep 2022 | - | $6.55 M(-52.6%) |
| Jun 2022 | - | $13.80 M(+67.8%) |
| Mar 2022 | - | $8.23 M(+112.4%) |
| Dec 2021 | $3.87 M(+515.7%) | $3.87 M(-34.2%) |
| Sep 2021 | - | $5.88 M(-47.7%) |
| Jun 2021 | - | $11.24 M(+565.6%) |
| Mar 2021 | - | $1.69 M(+168.5%) |
| Dec 2020 | $629.00 K(-79.5%) | $629.00 K(-94.8%) |
| Sep 2020 | - | $12.07 M(-34.6%) |
| Jun 2020 | - | $18.46 M(+59.6%) |
| Mar 2020 | - | $11.56 M(+276.9%) |
| Dec 2019 | $3.07 M(-82.0%) | $3.07 M(+88.6%) |
| Sep 2019 | - | $1.63 M(-79.7%) |
| Jun 2019 | - | $8.00 M(-26.0%) |
| Mar 2019 | - | $10.81 M(-36.7%) |
| Dec 2018 | $17.09 M(-9.7%) | $17.09 M(+77.2%) |
| Sep 2018 | - | $9.64 M(+93.7%) |
| Jun 2018 | - | $4.98 M(-56.5%) |
| Mar 2018 | - | $11.46 M(-39.4%) |
| Dec 2017 | $18.92 M(+140.9%) | $18.92 M(+254.5%) |
| Sep 2017 | - | $5.34 M(-15.5%) |
| Jun 2017 | - | $6.32 M(+41.1%) |
| Mar 2017 | - | $4.48 M(-43.0%) |
| Dec 2016 | $7.85 M(+135.4%) | $7.85 M(+28.9%) |
| Sep 2016 | - | $6.09 M(-29.7%) |
| Jun 2016 | - | $8.66 M(+26.2%) |
| Mar 2016 | - | $6.86 M(+105.7%) |
| Dec 2015 | $3.34 M(-2.9%) | $3.34 M(+22.0%) |
| Sep 2015 | - | $2.73 M(-8.4%) |
| Jun 2015 | - | $2.99 M(+25.3%) |
| Mar 2015 | - | $2.38 M(-30.6%) |
| Dec 2014 | $3.44 M(+166.3%) | $3.44 M(+132.9%) |
| Sep 2014 | - | $1.48 M(-16.6%) |
| Jun 2014 | - | $1.77 M(-50.9%) |
| Mar 2014 | - | $3.60 M(+179.3%) |
| Dec 2013 | $1.29 M(-32.5%) | $1.29 M(-42.7%) |
| Sep 2013 | - | $2.25 M(-57.9%) |
| Jun 2013 | - | $5.35 M(+39.9%) |
| Mar 2013 | - | $3.83 M(+100.1%) |
| Dec 2012 | $1.91 M(+89.3%) | $1.91 M(+8.8%) |
| Sep 2012 | - | $1.76 M(+190.6%) |
| Jun 2012 | - | $605.00 K(-32.0%) |
| Mar 2012 | - | $890.00 K(-11.9%) |
| Dec 2011 | $1.01 M(+535.2%) | $1.01 M(+133.3%) |
| Sep 2011 | - | $433.00 K(+49.8%) |
| Jun 2011 | - | $289.00 K(-6.5%) |
| Mar 2011 | - | $309.00 K(+94.3%) |
| Dec 2010 | $159.00 K(-1.9%) | $159.00 K(+1.3%) |
| Sep 2010 | - | $157.00 K(+22.7%) |
| Jun 2010 | - | $128.00 K(-46.9%) |
| Mar 2010 | - | $241.00 K(+48.8%) |
| Dec 2009 | $162.00 K(-52.9%) | $162.00 K(-29.9%) |
| Sep 2009 | - | $231.00 K(-58.3%) |
| Jun 2009 | - | $554.00 K(-19.6%) |
| Mar 2009 | - | $689.00 K(+100.3%) |
| Dec 2008 | $344.00 K(-76.1%) | $344.00 K(-51.9%) |
| Sep 2008 | - | $715.00 K(-44.4%) |
| Jun 2008 | - | $1.28 M(-7.6%) |
| Mar 2008 | - | $1.39 M(-3.3%) |
| Dec 2007 | $1.44 M(+86.1%) | $1.44 M(+187.4%) |
| Sep 2007 | - | $500.00 K(-30.3%) |
| Jun 2007 | - | $717.00 K(+24.3%) |
| Mar 2007 | - | $577.00 K(-25.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2006 | $772.00 K(+25.7%) | $772.00 K(+116.2%) |
| Sep 2006 | - | $357.00 K(+142.9%) |
| Jun 2006 | - | $147.00 K(-62.1%) |
| Mar 2006 | - | $388.00 K(-36.8%) |
| Dec 2005 | $614.00 K(-11.9%) | $614.00 K(-34.9%) |
| Sep 2005 | - | $943.00 K(+50.6%) |
| Jun 2005 | - | $626.00 K(+13.2%) |
| Mar 2005 | - | $553.00 K(-20.7%) |
| Dec 2004 | $697.00 K(+46.4%) | $697.00 K(-0.6%) |
| Sep 2004 | - | $701.00 K(+87.4%) |
| Jun 2004 | - | $374.00 K(-68.9%) |
| Mar 2004 | - | $1.20 M(+152.3%) |
| Dec 2003 | $476.00 K(+77.6%) | $476.00 K(+61.4%) |
| Sep 2003 | - | $295.00 K(-21.8%) |
| Jun 2003 | - | $377.00 K(+107.1%) |
| Mar 2003 | - | $182.00 K(-32.1%) |
| Dec 2002 | $268.00 K(-22.8%) | $268.00 K(+9.8%) |
| Sep 2002 | - | $244.00 K(-28.4%) |
| Jun 2002 | - | $341.00 K(+150.4%) |
| Mar 2002 | - | $136.20 K(-60.7%) |
| Dec 2001 | $347.00 K(+5.5%) | $347.00 K(-46.9%) |
| Sep 2001 | - | $653.30 K(-2.0%) |
| Jun 2001 | - | $666.80 K(+260.4%) |
| Mar 2001 | - | $185.00 K(-43.8%) |
| Dec 2000 | $329.00 K(-68.0%) | $329.00 K(-53.1%) |
| Sep 2000 | - | $701.70 K(-58.4%) |
| Jun 2000 | - | $1.69 M(+86.1%) |
| Mar 2000 | - | $907.30 K(-11.9%) |
| Dec 1999 | $1.03 M(-20.8%) | $1.03 M(-6.4%) |
| Sep 1999 | - | $1.10 M(0.0%) |
| Jun 1999 | - | $1.10 M(-15.4%) |
| Mar 1999 | - | $1.30 M(0.0%) |
| Dec 1998 | $1.30 M(-18.8%) | $1.30 M(+8.3%) |
| Sep 1998 | - | $1.20 M(-7.7%) |
| Jun 1998 | - | $1.30 M(-23.5%) |
| Mar 1998 | - | $1.70 M(+6.3%) |
| Dec 1997 | $1.60 M(-30.4%) | $1.60 M(0.0%) |
| Sep 1997 | - | $1.60 M(+77.8%) |
| Jun 1997 | - | $900.00 K(-25.0%) |
| Mar 1997 | - | $1.20 M(-47.8%) |
| Dec 1996 | $2.30 M(-69.3%) | $2.30 M(+91.7%) |
| Sep 1996 | - | $1.20 M(-73.9%) |
| Jun 1996 | - | $4.60 M(-9.8%) |
| Mar 1996 | - | $5.10 M(-32.0%) |
| Dec 1995 | $7.50 M(+21.0%) | $7.50 M(-15.7%) |
| Sep 1995 | - | $8.90 M(-6.3%) |
| Jun 1995 | - | $9.50 M(-1.0%) |
| Mar 1995 | - | $9.60 M(+54.8%) |
| Dec 1994 | $6.20 M(-15.1%) | $6.20 M(-13.9%) |
| Sep 1994 | - | $7.20 M(-29.4%) |
| Jun 1994 | - | $10.20 M(+251.7%) |
| Mar 1994 | - | $2.90 M(-60.3%) |
| Dec 1993 | $7.30 M(+1116.7%) | $7.30 M(+461.5%) |
| Sep 1993 | - | $1.30 M(-31.6%) |
| Jun 1993 | - | $1.90 M(+216.7%) |
| Mar 1993 | - | $600.00 K(0.0%) |
| Dec 1992 | $600.00 K(+50.0%) | $600.00 K(+100.0%) |
| Sep 1992 | - | $300.00 K(-57.1%) |
| Jun 1992 | - | $700.00 K(+133.3%) |
| Mar 1992 | - | $300.00 K(-25.0%) |
| Dec 1991 | $400.00 K(0.0%) | $400.00 K(+100.0%) |
| Sep 1991 | - | $200.00 K(0.0%) |
| Jun 1991 | - | $200.00 K(+100.0%) |
| Mar 1991 | - | $100.00 K(-75.0%) |
| Dec 1990 | $400.00 K(+33.3%) | $400.00 K(-20.0%) |
| Sep 1990 | - | $500.00 K(+25.0%) |
| Jun 1990 | - | $400.00 K(+100.0%) |
| Mar 1990 | - | $200.00 K(-33.3%) |
| Dec 1989 | $300.00 K | $300.00 K(0.0%) |
| Sep 1989 | - | $300.00 K(0.0%) |
| Jun 1989 | - | $300.00 K |
FAQ
- What is Heron Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Heron Therapeutics?
- What is Heron Therapeutics annual accounts payable year-on-year change?
- What is Heron Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Heron Therapeutics?
- What is Heron Therapeutics quarterly accounts payable year-on-year change?
What is Heron Therapeutics annual accounts payable?
The current annual accounts payable of HRTX is $3.80 M
What is the all time high annual accounts payable for Heron Therapeutics?
Heron Therapeutics all-time high annual accounts payable is $18.92 M
What is Heron Therapeutics annual accounts payable year-on-year change?
Over the past year, HRTX annual accounts payable has changed by +$211.00 K (+5.88%)
What is Heron Therapeutics quarterly accounts payable?
The current quarterly accounts payable of HRTX is $10.19 M
What is the all time high quarterly accounts payable for Heron Therapeutics?
Heron Therapeutics all-time high quarterly accounts payable is $18.92 M
What is Heron Therapeutics quarterly accounts payable year-on-year change?
Over the past year, HRTX quarterly accounts payable has changed by -$38.00 K (-0.37%)